Mavatar Enters Research Collaboration with Sobi
Mavatar, a global specialist in AI- and data-driven precision medicine solutions, today announces the start of a non-clinical research collaboration with Sobi, a global biopharmaceutical company focused on rare diseases.
The collaboration will explore interferon gamma (IFNγ)-associated biological pathways using Mavatar’s large-scale analysis platform, Mavatar Discovery, which integrates and contextualizes publicly available transcriptomic datasets.
The research aims to generate structured, data-driven insights that can support scientific understanding in selected disease areas.
“We are pleased to collaborate with Sobi, whose deep commitment to rare diseases aligns strongly with our mission,” said Johan Juhlin, CEO and Co-founder of Mavatar.
“Through advanced analytics of public transcriptomic data, we aim to contribute to a clearer understanding of IFNγ-driven mechanisms across relevant biological contexts.”
By leveraging Mavatar’s analytical frameworks, the project will investigate IFNγ-related molecular patterns across selected datasets, supporting broader scientific exploration in immune-mediated and rare disease research.
“Understanding the underlying biology of rare and immune-mediated conditions is essential for advancing research in the field,” said Emmanuel Monet, Head Medical Science Strategy, Sobi.
“Through this collaboration, we aim to further strengthen our scientific knowledge base using structured, data-driven analyses.”
This collaboration strengthens Mavatar’s expanding work within rare disease and immunology - areas where AI- and data-driven research can help accelerate insight generation.
Mavatar Discovery is a web-based research platform designed to support data-driven exploration of disease biology. Powered by Mavatar’s proprietary Deep Integrated Network Analysis (DINA) technology, the platform integrates large-scale, publicly available transcriptomic data into structured, biologically meaningful networks. Mavatar Discovery is used by researchers across academia, pharmaceutical companies, and biotech to support hypothesis generation, exploration of disease mechanisms, and biomarker and target research in a transparent and reproducible manner.
For more information contact:
Linda Wakeham
Chife Marketing & Communication Officer
linda.wakeham@mavatar.com
About Mavatar:
Mavatar is a global specialist in AI-driven precision medicine solutions for all diseases. Built on over 20 years of scientific research, Mavatar’s proprietary DINA (Deep Integrated Network Analysis) framework powers two flagship platforms: Mavatar Discovery for accelerating disease and drug research, and Mavatar Precision for delivering personalized treatment recommendations in clinical care. By creating digital twins of both patients and diseases, Mavatar enables data-driven decisions that improve treatment outcomes, optimize clinical trials, and reduce healthcare waste. Headquartered in Stockholm, Sweden, Mavatar is driving the future of truly personalized, scalable healthcare across all disease areas.
Tags:
